再鼎医药(09688.HK)2025年亏损净额同比收窄31.73%

Core Viewpoint - Zai Ding Pharmaceutical (09688.HK) reported total revenue of approximately $460 million for the year ending December 31, 2025, representing a year-on-year growth of 15.33% [1] - The net loss narrowed to approximately $176 million, a decrease of 31.73% year-on-year, with a loss per share of $0.16 [1] Revenue Summary - Product revenue netted approximately $457 million, reflecting a 15% year-on-year increase [1] - The growth in product revenue was primarily driven by increased sales of Ding You Le and Niu Zai Le [1]